Vaccine Partnering Terms and Agreements -





Published: July 2014 | Edition: 7 | Pages: 1021 (including appendices)

 

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in vaccine and adjuvant partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for vaccines

 

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 880 links to online copies of actual vaccine deals along with contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading vaccine deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since January 2009. The chapter is organized by specific vaccine and adjuvant technology type. Where contract available, the deal links via Weblink to an online version of the deal record providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

 

In addition, a comprehensive appendix is provided organized by vaccine partnering company A-Z, stage of development, theray area and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

 

Vaccine Partnering Terms and Agreements includes:

 

  • Trends in vaccine dealmaking in the biopharma industry since 2009
  • Analysis of vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life vaccine deals
  • Access to over 800 vaccine deal documents
  • The leading vaccine deals by value since 2009
  • Most active vaccine dealmakers since 2009
  • The leading vaccine partnering resources

 

In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target
  • Specific technology type

 

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 880 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise vaccine rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Vaccine Partnering Terms and Agreements provides the reader with the following key benefits:   

  • In-depth understanding of vaccine and adjuvant deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of vaccine agreements with numerous real life case studies
  • Comprehensive access to over 880 actual vaccine deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual vaccine contracts enter into by the leading 50 big pharma and top 50 big biotech companies
  • Identify leading vaccine deals by value since 2009
  • Identify the most active vaccine dealmakers since 2009
  • Insight into the terms included in a vaccine agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


 

 

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in vaccine dealmaking 

 

2.1. Introduction

2.2. Vaccine partnering over the years

2.3. Big pharma vaccine dealmaking activity

2.4. Big biotech vaccine dealmaking activity

2.5. Most active in vaccine partnering

2.6. Vaccine partnering by deal type

2.7. Vaccine partnering by disease type

2.8. Average deal terms for vaccine partnering

2.8.1 Vaccine partnering headline values

2.8.2 Vaccine deal upfront payments

2.8.3 Vaccine deal milestone payments

2.8.4 Vaccine royalty rates

2.9. The anatomy of vaccine partnering

2.9. The anatomy of a vaccine deal

2.9. a. Case study 1: Stemline Therapeutics- University of Pittsburgh: March 2012

2.9.b. Case study 2: Agenus Bio- NewVac: December 2011

 

Chapter 3 – Leading vaccine deals 

3.1. Introduction

3.2. Top vaccine deals by value

3.3. Top vaccine deals involving big pharma

3.4. Top vaccine deals involving big biotech

 

Chapter 4 – Big pharma vaccine deals 

 

4.1. Introduction

4.2. How to use big pharma vaccine partnering deals

4.3. Big pharma vaccine partnering company profiles

Abbott

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Otsuka

Pfizer

Ranbaxy Laboratories

Roche

Sanofi

Shionogi

Takeda

Teva

 

Chapter 5 – Big biotech vaccine deals 

 

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech vaccine partnering company profiles

Bavarian Nordic

Cangene

Dendreon

Elan

Emergent BioSolutions

Genmab

Morphosys

Spectrum Pharmaceuticals

 

Chapter 6 – Vaccine contracts dealmaking directory 

 

6.1. Introduction

 

6.2. Company A-Z

 

Achaogen

Adamis Pharmaceuticals

Advaxis

Agenus Bio

Antigenics

Argos Therapeutics

Astellas Pharma

Avecia Biologics

AVI Pharma

Avimex

Bio-Matrix Scientific

BioCryst Pharmaceuticals

Biomedical Advanced Research and Development Authority

Bristol-Myers Squibb

Cadila Pharmaceuticals

Cedars-Sinai Medical Center

CPL Biologicals

Crucell

Dana-Farber Cancer Institute

Defense Threat Reduction Agency

Dendreon

Department of Health and Human Services

Department of Homeland Security

Diosynth

Dynavax Technologies

Elan

Emergent BioSolutions

Entest BioMedical

Fraunhofer USA

Galena Biopharma

Genocea Biosciences

GenVec

Gilead Sciences

GlaxoSmithKline

GlaxoSmithKline Biologicals

GlobeImmune

Gynecologic Oncology Group

Heat Biologics

Henry Schein

Hollister-Stier Labs

IBioPharma

ID Biomedical

ImmunoCellular Therapeutics

Inovio Pharmaceuticals

Isconova

ISSI-Strategy

Janssen Alzheimer Immunotherapy

Janssen Pharmaceutica NV

Johnson & Johnson

Kirin Pharma

Kyowa Hakko Kirin

LG Life Sciences

Maxygen

MD Anderson Cancer Center

Medarex

Merck and Co

Merix Bioscience

MorphoSys

Nabi Biopharmaceuticals

National Institutes of Health

NewVac

Novavax

Numoda

Ohio State University

Omnimmune

OncoSec Medical

Ortho-McNeil

Perseid Therapeutics

PharmAthene

RXi Pharmaceuticals

SIGA Technologies

Stemline Therapeutics

Symphony Dynamo

Talecris Biotherapeutics

The Regents of the University of California

Therinject

University of Connecticut

University of Miami

University of Pittsburgh

University of Washington

Vical

Xencor

 

6.3. By stage of development

 

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

 

6.4. By deal type

 

Asset purchase

Co-development

Collaborative R&D

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Grant

Joint venture

Licensing

Manufacturing

Marketing

Material transfer

Option

Research

Settlement

Supply

Technology transfer

Termination

Warranty

6.5. By therapy area

Gynaecology

Hospital care

Immunology

Infectives

Oncology

Psychiatry

Respiratory

 

Chapter 7 – Vaccine dealmaking directory by technology type 

 

7.2. Deals by technology type

Vaccines

Adjuvant

 

Chapter 8 – Vaccine partnering resource center 

 

8.1. Online vaccine partnering

8.2. Vaccine partnering events

8.3. Further reading on vaccine dealmaking

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from Current Partnering

Order Form – Reports

 

Table of figures 

 

Figure 1: Vaccine partnering since 2009

Figure 2: Big pharma – top 50 – vaccine deals 2009 to 2014

Figure 3: Big pharma vaccine deal frequency – 2009 to 2014

Figure 4: Big biotech – vaccine deals 2009 to 2014

Figure 5: Big biotech vaccine deal frequency – 2009 to 2014

Figure 6: Active vaccine dealmaking activity– 2009 to 2014

Figure 7: Vaccine partnering by deal type since 2009

Figure 8: Vaccine partnering by disease type since 2009

Figure 9: Vaccine partnering by infectives target since 2009

Figure 10: Vaccine partnering by oncology target since 2009

Figure 11: Vaccine deals with a headline value – by stage of development

Figure 12: Vaccine deal headline value distribution, US$million – discovery stage

Figure 13: Vaccine deal headline value distribution, US$million – preclinical stage

Figure 14: Vaccine deal headline value distribution, US$million – phase I stage

Figure 15: Vaccine deal headline value distribution, US$million – phase II stage

Figure 16: Vaccine deal headline value distribution, US$million – phase III stage

Figure 17: Vaccine deal headline value distribution, US$million – marketed stage

Figure 18: Vaccine deal headline value – median value by stage of development

Figure 19: Vaccine deals with upfront payment values – by stage of development

Figure 20: Vaccine deal upfront payment distribution, US$million – discovery stage deals

Figure 21: Vaccine deal upfront payment distribution, US$million – prelinical stage deals

Figure 22: Vaccine deal upfront payment distribution, US$million – phase I stage deals

Figure 23: Vaccine deal upfront payment distribution, US$million – phase II stage deals

Figure 24: Vaccine deal upfront payment distribution, US$million – phase III stage deals

Figure 25: Vaccine deal upfront payment distribution, US$million – marketed stage deals

Figure 26: Vaccine deal upfront value – median value by stage of development

Figure 27: Vaccine deals with milestone payment – by stage of development

Figure 28: Vaccine deal milestone payment distribution, US$million – discovery stage deals

Figure 29: Vaccine deal milestone payment distribution, US$million – prelinical stage deals

Figure 30: Vaccine deal milestone payment distribution, US$million – phase I stage deals

Figure 31: Vaccine deal milestone payment distribution, US$million – phase II stage deals

Figure 32: Vaccine deal milestone payment distribution, US$million – phase III stage deals

Figure 33: Vaccine deal milestone payment distribution, US$million – marketed stage deals

Figure 34: Vaccine deals with royalty rates

Figure 35: Components of the typical vaccine deal structure

Figure 36: Top vaccine deals by value since 2009

Figure 37: Top vaccine deals signed by big pharma value since 2009

Figure 38: Top vaccine deals signed by big biotech value since 2009

Figure 39: Online partnering resources

Figure 40: Forthcoming partnering events